Orbimed Advisors SC 13D ArriVent Biopharma / ORBIMED ADVISORS ownership change

Exhibit 1

JOINT FILING AGREEMENT

The undersigned hereby agree that the Statement on Schedule 13D, dated January 30, 2024, with respect to the common stock of ArriVent BioPharma, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be responsible for the timely filing of this Statement, and for the completeness and accuracy of the information concerning itself contained therein. This Joint Filing Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned have executed this Joint Filing Agreement as of the 5^th day of February 2024.

ORBIMED ADVISORS LLC
By:	/s/ Carl L. Gordon
	Name: Carl L. Gordon
	Title: Member
ORBIMED ASIA GP IV, L.P.
By:	ORBIMED ADVISORS IV LIMITED, its general partner
By:	/s/ Carl L. Gordon
	Name: Carl L. Gordon
	Title: Director of OrbiMed Advisors IV Limited
ORBIMED ADVISORS IV LIMITED
By:	/s/ Carl L. Gordon
	Name: Carl L. Gordon
	Title: Director
ORBIMED CAPITAL GP VIII LLC
By:	ORBIMED ADVISORS LLC, its managing member
By:	s/ Carl L. Gordon
	Name: Carl L. Gordon
	Title: Member of OrbiMed Advisors LLC